---
title: "Vraylar (cariprazine) in major depressive disorder: Clinical trials questions"
description: "Clinical trials questions on Vraylar (cariprazine) in major depressive disorder, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Study results. Questions: How effective is Vraylar added to an antidepressant for depression? How were the Vraylar trials in depression (MDD) designed? Which antidepressants were patients taking in the Vraylar MDD trials? Does Vraylar improve anhedonia in depression? 2 further questions follow. 6 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/clinical-trials"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Vraylar (cariprazine) in major depressive disorder: Clinical trials questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Vraylar](https://www.rxabbvie.com/pdf/vraylar_pi.pdf)

Questions that apply to every indication of Vraylar are on [Vraylar (cariprazine), all indications](https://www.evicenter.com/medical-information/vraylar).

## Study results

<a id="vraylar-mdd-efficacy"></a>

### How effective is Vraylar added to an antidepressant for depression?

> “<sup>§</sup>The efficacy of VRAYLAR in adjunctive MDD was evaluated in 2 trials in adult MDD patients with an inadequate response to 1 to 3 courses of prior antidepressant (ADT) therapy. In the 6-week trial, LS mean change from baseline in MADRS total score (primary endpoint) was -14.1 (VRAYLAR 1.5 mg/day + ADT; n=250) vs -11.5 (placebo + ADT; n=249), P<0.05; -13.1 for VRAYLAR 3 mg/day + ADT (n=252; dose was not statistically significant). In the 8-week trial, LS mean change from baseline in MADRS total score (primary endpoint) was -14.6 (VRAYLAR 2-4.5 mg/day + ADT; n=271) vs -12.5 (placebo + ADT; n=264), P<0.05; -13.4 for VRAYLAR 1-2 mg/day + ADT (n=273; dose was not statistically significant).<sup>1</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) for major depressive disorder (aMDD), captured 2026-11-13](https://www.vraylarhcp.com/indication-overview/amdd#:~:text=efficacy%20of%20VRAYLAR%20in%20adjunctive,%28n%3D273%3B%20dose%20was%20not%20statistically)

> “Study 10: In a 6-week, placebo-controlled trial (N = 751) involving two fixed doses of VRAYLAR 
> (1.5 mg per day or 3 mg per day) + ADT, VRAYLAR 1.5 mg + ADT was superior to placebo + ADT at 
> end of Week 6 on the MADRS total score. The treatment effect in the VRAYLAR 3 mg per day + ADT 
> group (vs. placebo + ADT) was not statistically significant.”

Source: [VRAYLAR: Prescribing information, page 43, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=43)

> “Study 11: An 8-week, placebo-controlled trial (N = 808) involved flexible doses of VRAYLAR 1 to 
> 2 mg per day + ADT or 2 to 4.5 mg per day + ADT. VRAYLAR 2 to 4.5 mg (mean dose was 2.6 mg) + 
> ADT was superior to placebo + ADT at end of Week 8 on the MADRS total score. The treatment effect 
> in the VRAYLAR 1 to 2 mg per day + ADT group (vs. placebo + ADT) was not statistically significant.”

Source: [VRAYLAR: Prescribing information, page 43, captured 2026-11-13](https://www.rxabbvie.com/pdf/vraylar_pi.pdf#page=43)

Note: The 2 to 4.5 mg/day range in the 8-week trial extends above the 3 mg/day maximum recommended dosage for MDD.

<a id="vraylar-anhedonia"></a>

### Does Vraylar improve anhedonia in depression?

> “Observed reduction in MADRS anhedonia subscale score in patients with major depressive disorder at Week 6 in a post-hoc analysis<sup>4</sup>**”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Efficacy as an Add-on for MDD, captured 2026-11-13](https://www.vraylarhcp.com/efficacy/amdd-efficacy#:~:text=Observed%20reduction%20in%20MADRS%20anhedonia,Week%206%20in%20a%20post%2Dhoc)

> “These analyses were not prespecified endpoints and were not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Efficacy as an Add-on for MDD, captured 2026-11-13](https://www.vraylarhcp.com/efficacy/amdd-efficacy#:~:text=These%20analyses%20were%20not%20prespecified,be%20regarded%20as%20statistically%20significant.)

> “**This was a post-hoc analysis of the primary endpoint (MADRS change from baseline to Week 6) and was not adjusted for multiplicity. The primary endpoint was change from baseline to Week 6 in MADRS total score. Results of a representative, pivotal, multicenter, randomized, placebo-controlled 6-week trial in adults with MDD (N=751). Patients were randomized in 3 arms: VRAYLAR 1.5 mg, VRAYLAR 3 mg, or placebo + ongoing ADT.<sup>1,4</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Efficacy as an Add-on for MDD, captured 2026-11-13](https://www.vraylarhcp.com/efficacy/amdd-efficacy#:~:text=%2A%2AThis%20was%20a%20post%2Dhoc%20analysis,mg%2C%20or%20placebo%20%2B%20ongoing)

Note: The page presents the subscale results as a figure; the captured text holds the heading and the analysis qualifications quoted here.

<a id="vraylar-anxiety-symptoms"></a>

### Does Vraylar reduce anxiety symptoms in depression (HAM-A)?

> “Observed reduction in anxiety symptom score in patients with major depressive disorder at Week 6<sup>2</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Efficacy as an Add-on for MDD, captured 2026-11-13](https://www.vraylarhcp.com/efficacy/amdd-efficacy#:~:text=Observed%20reduction%20in%20anxiety%20symptom,major%20depressive%20disorder%20at%20Week)

> “VRAYLAR is indicated in adults as adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). VRAYLAR is not approved for the treatment of anxiety disorders.<sup>1</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Efficacy as an Add-on for MDD, captured 2026-11-13](https://www.vraylarhcp.com/efficacy/amdd-efficacy#:~:text=VRAYLAR%20is%20indicated%20in%20adults%20as%20adjunctive%20therapy%20to%20antidepressants%20for%20the%20treatment%20of%20major%20depressive%20disorder%20%28MDD%29.%20VRAYLAR%20is%20not%20approved%20for%20the%20treatment%20of%20anxiety%20disorders.1,-HAM%2DA%20was%20an)

> “HAM-A was an additional efficacy endpoint in the 6-week adjunctive MDD trial. This prespecified endpoint was not adjusted for multiplicity. Therefore, treatment differences cannot be regarded as statistically significant.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Efficacy as an Add-on for MDD, captured 2026-11-13](https://www.vraylarhcp.com/efficacy/amdd-efficacy#:~:text=HAM%2DA%20was%20an%20additional%20efficacy,be%20regarded%20as%20statistically%20significant.)

Note: The page presents the HAM-A results as a figure; the captured text holds the heading and the analysis qualifications quoted here.

<a id="vraylar-quality-of-life"></a>

### Does Vraylar improve quality of life in depression (SF-12v2)?

> “Observed increase in health-related quality of life in patients with major depressive disorder at Week 6 in a health outcomes measure<sup>3,6</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Efficacy as an Add-on for MDD, captured 2026-11-13](https://www.vraylarhcp.com/efficacy/amdd-efficacy#:~:text=Observed%20increase%20in%20health%2Drelated%20quality,6%20in%20a%20health%20outcomes)

> “The 12-item Short Form version 2 Health Survey (SF-12v2) was a prespecified Health Outcome Measure in the 6-week adjunctive MDD trial. These data were not adjusted for multiplicity; therefore, treatment differences cannot be regarded as statistically significant.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Efficacy as an Add-on for MDD, captured 2026-11-13](https://www.vraylarhcp.com/efficacy/amdd-efficacy#:~:text=The%2012%2Ditem%20Short%20Form%20version,be%20regarded%20as%20statistically%20significant.)

Note: The page presents the SF-12v2 results as a figure; the captured text holds the heading and the analysis qualifications quoted here.

## Clinical trials

<a id="vraylar-mdd-trial-design"></a>

### How were the Vraylar trials in depression (MDD) designed?

> “Study design<sup>1,3</sup>
> Duration	N	Design	Doses Studied	Control	Primary Endpoint
> 6-Week	751	Fixed Dose	1.5 mg/day + ADT;
> 3 mg/day + ADT	Placebo + ADT	Mean change from baseline in MADRS total score at the end of Week 6
> 8-Week	808	Flexible Dose	1-2 mg/day + ADT
> Mean VRAYLAR dose was 1.4 mg/day;
>
> 2-4.5 mg/day + ADT
> Mean VRAYLAR dose was 2.6 mg/day	Placebo + ADT	Mean change from baseline in MADRS total score at the end of Week 8
>
> Both adjunctive MDD studies were randomized, double-blind, placebo-controlled, and evaluated the efficacy and safety of VRAYLAR in adult patients (mean age of 45 years, range 18-65 years) who met DSM-IV-TR or DSM-5 criteria for MDD, with or without symptoms of anxiety, and had an inadequate response to 1 to 3 courses of prior antidepressant (ADT) therapy.<sup>§</sup>
>
> <sup>§</sup>Inadequate response during antidepressant treatment was defined as less than 50% improvement to antidepressant treatment of adequate dose and duration.”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Efficacy as an Add-on for MDD, captured 2026-11-13](https://www.vraylarhcp.com/efficacy/amdd-efficacy#:~:text=MDD%20partial%20responders-,Study,of%20adequate%20dose%20and%20duration.)

<a id="vraylar-mdd-trial-antidepressants"></a>

### Which antidepressants were patients taking in the Vraylar MDD trials?

> “Patients enrolled were taking the most commonly used antidepressants, including<sup>||</sup>:
>
> sertraline
> fluoxetine
> bupropion
> escitalopram
> duloxetine
> citalopram
> desvenlafaxine
> venlafaxine”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Efficacy as an Add-on for MDD, captured 2026-11-13](https://www.vraylarhcp.com/efficacy/amdd-efficacy#:~:text=Patients%20enrolled%20were%20taking%20the,venlafaxine)

> “<sup>||</sup>These are not all of the ADTs patients were taking prior to and during the VRAYLAR MDD studies. Please see publications for complete list.<sup>3</sup>”

Source: [VRAYLAR: VRAYLAR® (cariprazine) Efficacy as an Add-on for MDD, captured 2026-11-13](https://www.vraylarhcp.com/efficacy/amdd-efficacy#:~:text=are%20not%20all%20of%20the,Please%20see%20publications%20for%20complete)

## Related pages
- [Medical information: Vraylar (cariprazine): Major depressive disorder](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder)
- [Indication](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/indication)
- [Safety](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/safety)
- [Specific populations](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/vraylar--major-depressive-disorder/access-and-coverage)
